BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 22441567)

  • 1. Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer.
    Xie CY; Xu YP; Jin W; Lou LG
    Anticancer Drugs; 2012 Aug; 23(7):698-705. PubMed ID: 22441567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells.
    Sun X; Lou LG; Sui DH; Wu XH
    Asian Pac J Cancer Prev; 2014; 15(22):9939-43. PubMed ID: 25520132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer.
    Fahham D; Weiss ID; Abraham M; Beider K; Hanna W; Shlomai Z; Eizenberg O; Zamir G; Izhar U; Shapira OM; Peled A; Wald O
    J Thorac Cardiovasc Surg; 2012 Nov; 144(5):1167-1175.e1. PubMed ID: 22925564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma.
    Carter CA; Chen C; Brink C; Vincent P; Maxuitenko YY; Gilbert KS; Waud WR; Zhang X
    Cancer Chemother Pharmacol; 2007 Feb; 59(2):183-95. PubMed ID: 16724239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic antitumor efficacy of sequentially combined paclitaxel with sorafenib in vitro and in vivo NSCLC models harboring KRAS or BRAF mutations.
    Zhang XH; Shin JY; Kim JO; Oh JE; Yoon SA; Jung CK; Kang JH
    Cancer Lett; 2012 Sep; 322(2):213-22. PubMed ID: 22433711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Inhibitory effect of imrecoxib combined with lobaplatin on tumor growth and lymph node metastasis of human lung cancer xenografts in nude mice].
    Wang DC; Wang LC; Wang LJ; Chen G; Zhao YX; Zhao ZF; Li YH
    Zhonghua Zhong Liu Za Zhi; 2016 May; 38(5):340-5. PubMed ID: 27188605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atorvastatin sensitizes human non-small cell lung carcinomas to carboplatin via suppression of AKT activation and upregulation of TIMP-1.
    Chen J; Lan T; Hou J; Zhang J; An Y; Tie L; Pan Y; Liu J; Li X
    Int J Biochem Cell Biol; 2012 May; 44(5):759-69. PubMed ID: 22305890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents.
    Chan DC; Gera L; Stewart JM; Helfrich B; Zhao TL; Feng WY; Chan KK; Covey JM; Bunn PA
    Clin Cancer Res; 2002 May; 8(5):1280-7. PubMed ID: 12006549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TNF-related apoptosis-inducing ligand enhances vinorelbine-induced apoptosis and antitumor activity in a preclinical model of non-small cell lung cancer.
    Zhu K; Fang W; Chen Y; Lin S; Chen X
    Oncol Rep; 2014 Sep; 32(3):1234-42. PubMed ID: 25017445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
    Li YY; Chang JW; Chou WC; Liaw CC; Wang HM; Huang JS; Wang CH; Yeh KY
    Lung Cancer; 2008 Feb; 59(2):180-91. PubMed ID: 17900752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of lobaplatin as a single agent and in combination with TRAIL on the growth of triple-negative p53-mutated breast cancers in vitro.
    Engel JB; Martens T; Hahne JC; Häusler SF; Krockenberger M; Segerer S; Djakovic A; Meyer S; Dietl J; Wischhusen J; Honig A
    Anticancer Drugs; 2012 Apr; 23(4):426-36. PubMed ID: 22314264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
    Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cationic liposome-mediated nitric oxide synthase gene therapy enhances the antitumor effects of cisplatin in lung cancer.
    Ye S; Yang W; Wang Y; Ou W; Ma Q; Yu C; Ren J; Zhong G; Shi H; Yuan Z; Su X; Zhu W
    Int J Mol Med; 2013 Jan; 31(1):33-42. PubMed ID: 23128378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lobaplatin arrests cell cycle progression, induces apoptosis and alters the proteome in human cervical cancer cell Line CaSki.
    Li X; Ran L; Fang W; Wang D
    Biomed Pharmacother; 2014 Apr; 68(3):291-7. PubMed ID: 24239273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lobaplatin suppresses proliferation and induces apoptosis in the human colorectal carcinoma cell Line LOVO in vitro.
    Dai HY; Liu L; Qin SK; He XM; Li SY
    Biomed Pharmacother; 2011 Jun; 65(3):137-41. PubMed ID: 21612887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts.
    Teicher BA; Chen V; Shih C; Menon K; Forler PA; Phares VG; Amsrud T
    Clin Cancer Res; 2000 Mar; 6(3):1016-23. PubMed ID: 10741729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells.
    Hermann TW; Yen WC; Tooker P; Fan B; Roegner K; Negro-Vilar A; Lamph WW; Bissonnette RP
    Lung Cancer; 2005 Oct; 50(1):9-18. PubMed ID: 15993980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer Mechanism of Lobaplatin as Monotherapy and in Combination with Paclitaxel in Human Gastric Cancer.
    Hua S; Kong X; Chen B; Zhuang W; Sun Q; Yang W; Liu W; Zhang Y
    Curr Mol Pharmacol; 2018; 11(4):316-325. PubMed ID: 30101722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies.
    Shalinsky DR; Brekken J; Zou H; Bloom LA; McDermott CD; Zook S; Varki NM; Appelt K
    Clin Cancer Res; 1999 Jul; 5(7):1905-17. PubMed ID: 10430098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of a protein kinase C inhibitor combined with cisplatin on non-small cell lung cancer].
    Gao ZQ; Han BH; Sha HF; Shi ZY; Yang XH; Feng JX
    Zhonghua Jie He He Hu Xi Za Zhi; 2010 Apr; 33(4):284-8. PubMed ID: 20646461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.